Does Critical Illness Change Levofloxacin Pharmacokinetics?

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1459-1463

  Roberts, Jason A ^a,b   Cotta, Menino Osbert ^a,b   Cojutti, Piergiorgio ^c,d   Lugano, Manuela ^d   Rocca, Giorgio Della ^d   Pea, Federico ^c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG INDICATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; TERTIARY CARE CENTER; BACTERIAL PNEUMONIA; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; THEORETICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEVOFLOXACIN; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, THEORETICAL; MONTE CARLO METHOD; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84960405071     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02610-15     Document Type: Article

References (15)

1. Fish DN, Chow AT. 1997. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32:101-119. http://dx.doi.org/10.2165/00003088-199732020-00002.
2. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M. 1998. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 279:125-129. http://dx.doi.org/10.1001/jama.279.2.125.
3. Boselli E, Breilh D, Rimmele T, Djabarouti S, Saux MC, Chassard D, Allaouchiche B. 2005. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med 33:104-109. http://dx.doi.org/10.1097/01.CCM.0000150265.42067.4C.
4. Furlanut M, Brollo L, Lugatti E, Di Qual E, Dolcet F, Talmassons G, Pea F. 2003. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother 51:101-106. http://dx.doi.org/10.1093/jac/dkg035.
5. Rebuck JA, Fish DN, Abraham E. 2002. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22:1216-1225. http://dx.doi.org/10.1592/phco.22.15.1216.33484.
6. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Wong FA, Corrado M. 1998. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother 42:1098-1104.
7. Pea F, Di Qual E, Cusenza A, Brollo L, Baldassarre M, Furlanut M. 2003. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 42:589-598. http://dx.doi.org/10.2165/00003088-200342060-00008.
8. Tatarinova T, Neely M, Bartroff J, Van Guilder M, Yamada W, Bayard D, Jelliffe R, Leary R, Chubatiuk A, Schumitzky A. 2013. Two general methods for population pharmacokinetic modeling: Non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn 40:189-199. http://dx.doi.org/10.1007/s10928-013-9302-8.
9. Neely MN, Van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34:467-476. http://dx.doi.org/10.1097/FTD.0b013e31825c4ba6.
10. Tanigawara Y, Nomura H, Kagimoto N, Okumura K, Hori R. 1995. Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biol Pharm Bull 18: 315-320. http://dx.doi.org/10.1248/bpb.18.315.
11. Chien SC, Chow AT, Natarajan J, Williams RR, Wong FA, Rogge MC, Nayak RK. 1997. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 41:1562-1565.
12. Kiser TH, Hoody DW, Obritsch MD, Wegzyn CO, Bauling PC, Fish DN. 2006. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob Agents Chemother 50:1937-1945. http://dx.doi.org/10.1128/AAC.01466-05.
13. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. 2004. Relationship between fluoroquinolone area under the curve: Minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 189:1590-1597. http://dx.doi.org/10.1086/383320.
14. Odenholt I, Cars O. 2006. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: Simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 58:960-965. http://dx.doi.org/10.1093/jac/dkl356.
15. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/v-5.0-Breakpoint-Table-01.pdf.